Abstract LB252: Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcomain vivomodels
Sign Up to like & getrecommendations! Published in 2021 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2021-lb252
Abstract: Background. Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Copanlisib was approved for use by the FDA in the treatment… read more here.
Keywords: copanlisib; phosphoinositide kinase; pan class; pi3k ... See more keywords